Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — ASCO 2023
15 slides from Sutro Biopharma's conference presentation, 2023
Slide 1: Luveltamab Tazevibulin (STRO-002) Safety and Efficacy in Recurrent Epithelial Ovarian Cancer
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Safety and Efficacy in a Broad Distribution of FOLRα Expression in Patients With Recurrent Epithelial Ovarian Cancer: Update of STRO-002-GM1 Phase 1 Dose Expansion Cohort Ana Oaknin, Lorena Fariñas-Madrid, Carm
Slide 2: Recurrent ovarian cancer remains an area of high unmet medical need
Recurrent ovarian cancer remains an area of high unmet medical need • Standard chemotherapy treatment in the platinum-resistant setting provides limited disease control and survival (ORR of 10%–15%, median PFS 3–4 months, and median OS ~12 months)1 Luveltamab tazevibulin • Targeted therapy (eg, anti
Slide 3: Luveltamab tazevibulin is a precisely designed ADC targeting lower FolRα expression
Luveltamab tazevibulin is a precisely designed (ADC) effective in targeting lower levels of FolRα-expression SUTRO Cell-Free Platform Luveltamab tazevibulin Luveltamab Design Delivery or STRO-0021 Linker-payload position Cytotoxic tumor activity Ovarian Precise, stable position of cathepsin B tumor
Slide 4: STRO-002-GM1: phase 1 dose expansion cohort in recurrent epithelial ovarian cancer
STRO-002-GM1: phase 1 dose expansion cohort of luveltamab tazevibulin in recurrent epithelial ovarian cancer designed to optimize dose NCT03748186 • Recurrent disease Luveltamab ‒ Platinum resistant 1–3 prior regimens or 4.3 mg/kg Q3W platinum-sensitive n=23 • Primary endpoint: ORR by 2–3 prior regi
Slide 5: Analysis populations include all comers and FolRα selected (TPS >25%)
Analysis populations include all comers (unselected for FolRα) and FolRα selected (TPS >25%) RECIST v1.1 evaluable • FolRα expression retrospectively At least 1 post-baseline scan n=32 determined using IHC* on fresh or FolRα >25% by TPS archival tissue required (TPS >25%) n=35 • TPS is the percentag
Slide 6: Patient population has received multiple lines of platinum therapy
Patient population have received multiple lines of platinum therapy and majority received prior bevacizumab and PARP inhibitors 4.3 mg/kg 5.2 mg/kg Total n=23 n=21 N=44 Median age (range), years 63 (39–91) 56 (40–72) 60 (39–91) ECOG PS, n (%) 0 11 (47.8) 13 (61.9) 24 (54.5) 1 12 (52.2) 8 (38.1) 20 (
Slide 7: Majority of patients received 5 or more cycles; few discontinued due to adverse event
Majority of patients (61%) received 5 or more cycles and a small percentage discontinued due to adverse event 4.3 mg/kg 5.2 mg/kg (n=23) (n=21) Duration of treatment, months Median (range) 3.9 (0.7–16.7) 3.4 (1.0–12.9) Treatment Cycles, n (% of pts) 1 3 (13.0) 0 2 5 (21.7) 5 (23.8) 3 0 1 (4.8) 4 1 (
Slide 8: All-comers population demonstrated an ORR of 32% per RECIST v1.1
All-comers patient population (FolRα-unselected) demonstrated an ORR of 32% per RECIST v1.1 Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=41) 20% ORR: 31.7% in unselected pts • 37.5% for FoLRα >25% by TPS PR PR PR PR PR PR PR PR PR PR PR PR PR Disease control rate: 78% in
Slide 9: Patient responses occurred at both dose levels and were maintained with dose reductions
Patient responses occurred at both dose levels and were maintained with dose reductions Treatment Duration for Patients With at Least 1 Dose (N=44) 85 65 80 40 95 Individual patients treated with luveltamab 60 65 80 90 100 35 35 Dose Level, Q3W 95 95 95 2.3 mg/kg 80 15 2.9 mg/kg 90 99 1 3.5 mg/kg 40
Slide 10: Clinical activity seen at both doses across a broad range of FolRα expression levels
Clinical activity seen at both doses across a broad range of FolRα expression levels Treatment Response in RECIST-Evaluable Patients (N=41) All Patients and FolRα Selection Across TPS Scores FolRα >25% by TPS ORR 37.5% 40.0% 43.8% 31.7% 33.3% 31.3% 11.1% All Patients All (n = 41) All… FolRα- TPS TPS
Slide 11: Progression-free survival in the FolRα selected population
Luveltamab resulted in PFS of 6.1 months and median DOR of 5.5 months in the FolRα selected population (TPS >25%) 1.00 Progression-free survival 0.75 Median follow-up: 12.9 months 0.50 TPS >25% (n=35) 0.25 TPS ≤25% (n=9) All patients (n=44) 0.00 0 5 10 15 Time from the first treatment (months) All P
Slide 12: The most common TEAEs were neutropenia, nausea, fatigue, and arthralgia
The most common TEAEs (any grade) were neutropenia, nausea, fatigue, and arthralgia Most Common TEAEs (>25%) 4.3 mg/kg (n=23) 5.2 mg/kg (n=21) Total (N=44) n (%) Any Grade G3+ Any Grade G3+ Any Grade G3+ Patients reporting ≥1 event 23 (100) 18 (78.3) 21 (100) 20 (95.2) 44 (100) 38 (86.4) Hematologic
Slide 13: The TEAEs were predictable and manageable
The TEAEs were predictable and manageable TEAEs leading to dose reduction in 61.4% TEAEs leading to dose • Neutropenia* in 17 patients (39%) discontinuation in 3 patients (6.8%) ‒ Primarily G3/4 uncomplicated (abnormal • G3 fatigue lab value only) • G2 neuropathy† ‒ Febrile neutropenia in 2 patients
Slide 14: Conclusions
Conclusions • Luveltamab demonstrated robust clinical activity in patients with recurrent ovarian cancer • Data support FolRα cutoff of >25% as the optimum enrichment strategy ‒ ORR of 37.5%, PFS of 6.1 months, and DCR of 81% ‒ Allows treatment of ovarian cancer with a broad expression of FolRα (≈70
Slide 15: Acknowledgments
Acknowledgments • We thank the patients who participated in the study, their families, and the investigators and clinical research staff from the study centers • This study was sponsored by Sutro Biopharma, Inc. • Editorial support was provided by Min Yu, MD, of Parexel and funded by Sutro Biopharma